BITTREX-GLOBAL-GMBH
19.4.2022 09:03:08 CEST | Business Wire | Press release
Bittrex Global , a leading digital asset exchange, today welcomes the YellowHeart Protocol, an NFT platform poised to disrupt the ticketing and music industries, to its Initial Exchange Offering (IEO) platform, Bittrex Global Starting Block.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005320/en/
By using blockchain technologies, the YellowHeart Protocol is transforming what tickets can do and how they are created, sold and resold. Through the protocol, tickets are now offered as non-fungible tokens (NFTs) and enhanced with new capabilities enabled by the HRTS (pronounced “Hearts”) utility token. In contrast to traditional tickets, NFT tickets offer music, video, and engaging experiences. They enable artists to communicate directly with their fans and provide artists and venues with a share of the proceeds any time a ticket is resold.
The YellowHeart Protocol was created to bring together an entire ecosystem – composed of fans, artists, sports teams, brands, venues, event promoters, and more – to participate in this leap forward. This community comes together at the YellowHeart NFT marketplace, which can be accessed online at yh.io or via the YellowHeart mobile app for iOS and Android.
"In addition to ticket NFTs, the YellowHeart marketplace also offers music NFTs, collectible NFTs and community NFTs. It is already the premier place for musicians to participate in the NFT revolution, where artists like Maroon 5, The Beatles and XXXTentacion are being joined by a rapidly growing community of creators. With the launch of the HRTS token anyone can now join this community; HRTS token holders will be able to engage with each other in innovative ways, creating a decentralized, peer-to-peer platform for ticketing and entertainment. We are proud to be the YellowHeart ecosystem’s founding member and technology provider,” said Josh Katz, founder and CEO of YellowHeart LLC.
“We are pleased to have selected YellowHeart as the first project to be launched on Starting Block. It displays strong signs of promise in the new world of Web 3 ticketing and music, and we are happy to support and generate more awareness around this project through our IEO platform,” said Stephen Stonberg, CEO of Bittrex Global.
“After our team drove an exhaustive, multi-month IEO qualification process, HRTS was selected as the first project to debut on Starting Block for many reasons, including the quality of its token utility value, fully-diluted valuation, circulating supply and demand balance, product roadmap, team experience, brand, and partner accomplishments. We’re excited for the future of the YellowHeart Protocol and think the addition of the HRTS token to the Bittrex Global ecosystem will add significant value for all of our users, especially for those who are lucky enough to get into the IEO,” said Chris Sinkey, Listing Director and Chief Business Officer at Bittrex Global.
Emerging projects looking to IEO can utilize and leverage Bittrex Global’s reputation as one of the most secure digital asset exchanges in the world, committed to using advanced security protocols while remaining compliant with the wide range of regulatory measures across the globe.
The YellowHeart Protocol (HRTS) token sale will launch at 13:00 UTC on May 10, 2022 on Bittrex Global Starting Block.
Learn more: https://global.bittrex.com/Market/Index?MarketName=USDT-HRTS
Disclaimer:
This release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the issuer or selling security holder and that would contain detailed information about the issuer, as well as financial statements. There is no present intention to register any part of the present or proposed offering in the United States.
ABOUT YELLOWHEART PROTOCOL
The YellowHeart Protocol uses blockchain and NFT technologies to disrupt the ticketing industry and transform how artists and fans connect.
YellowHeart LLC is the technology provider and launch partner for the YellowHeart platform. Its marketplace for ticket NFTs, music NFTs, and community tokens attracts premier artists such as the Kings of Leon, Maroon 5, XXXTentacion, Brandi Carlile, ZHU, and more.
ABOUT BITTREX GLOBAL
Bittrex Global, the most secure digital asset exchange in the world, serves both retail and institutional clients, globally. Committed to helping users build wealth, Bittrex Global facilitates the purchase and trade of over 250 tokens. Through its use of cutting-edge technology, advanced security protocols, and a sophisticated elastic multi-stage wallet strategy the company provides a high-level experience for professional and novice customers alike. Bittrex Global is a key player in driving widespread adoption of secure and decentralized methods to building wealth while remaining compliant and adhering to the wide array of regulatory measures across the globe.
Bittrex Global GmbH is registered with the Financial Market Authority under Law of 3 October 2019 on Tokens and TT Service Providers (TVTG) in Liechtenstein to operate as a TT Exchange Service Provider, TT Token Depositary, and Token Issuer on behalf and for the account of third parties. Bittrex Global (Bermuda) Limited is regulated by the Bermuda Monetary Authority and licensed as a Class F Digital Asset Business under the Bermuda Digital Asset Business Act 2018 to operate as a digital asset exchange, provide custodial wallet services, and operate as a digital asset derivative exchange provider.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom